Reductions in plasma prolactin during acute erythropoietin administration

Neuroendocrinology Letters

Volumn 27, Issue 3, 2006, Pages 355-358

  Markianos, Manolis ^a   Kosmidis, Michael L ^a   Sfagos, Costas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Amyotrophic lateral sclerosis; Erythropoietin; Prolactin

Indexed keywords

DOPAMINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PROLACTIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; NEUROPROTECTION; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; STRIATE CORTEX;

EID: 33748693359     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, Gassmann M. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Nat Acad Sci USA 1995; 92:3717-3720.
2. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8:666-676.
3. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76:105-116.
4. Sakanaka M, Wen T-C, Matsuda S, Morishita S, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95:4635-4640.
5. Siren A-L, Fretelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenen S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98:4044-4049.
6. Iwasaki Y, Ikeda K, Ichikawa Y, Igarashi O, Iwamoto K, Kinoshita M. Protective effects of interleukin-3 and erythropoietin on motor neuron death after neonatal axotomy. Neurol Res 2002; 24:643-646.
7. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res 2005; 58:297-301.
8. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985; 6:245-249.
9. Schaeffer RM, Kokot F, Kuerne r B, Zech M, Heidland A. Normalization of elevated prolactin levels in hemodialysis patients on erythropoietin. Nephron 1988; 50:400-401.
10. Ramirez G, Bittle PA, Sanders H, Bercu BB. Hypothalamo-hypophyseal thyroid and gonadal function before and after erythropoietin therapy in dialysis patients. J Clin Endocrinol Metab 1992; 74:517-524.
11. Yeskan M, Tamer N, Cirit M, Turk S, Akhan G, Akkus I, Erkut I. Effect of recombinant human erythropoietin (r-HuEPO) therapy on plasma FT3, FT4, TSH, FSH, LH, free testosterone and prolactin levels in hemodialysis patients. Int J Artif Organs 1993; 15:585-589.
12. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y. Effects of erythropoietin on neuronal activity. J Neurochem 1999; 72:2565-2572.
13. Kawakami M, Iwasaki S, Sato K, Takahashi M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Comm 2000; 279:293-297.
14. Yamamoto M, Koshimura K, Kawaguchi M, Sohmiya M, Murakami Y, Kato Y. Stimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain slice. Neurosci Lett 2000; 292:131-133.
15. Csete M, Rodriguez L, Wilcox M, Chadalavada S. Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts. Neurosci Lett 2004; 359:124-126.
16. Genc S, Koroglu TF, Genc K. Erythropoietin and the nervous system. Brain Research 2004; 1000:19-31.
17. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewezuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8:495-505.
18. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp Biol Med 2003; 228:1-14.
19. Bellone G, Rollino C, Borsa S, Ferrero I, Martina G, Carbone A, Mareshi K, Quarello F, Piccoli G, Emanuelli G, Matera L. Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients. Proc Soc Exp Biol Med 2000; 223:367-371.
20. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, Woldt H, Falkai P, Knerlich F, Jacob S, von Ahsen N, Maier W, Ruther E, Cerami A, Becker W, Siren AL. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9:42-54.